Fierce Biotech
Scientists turn pig semen extract into eye drops that kill cancer in mice
The human eye is like an immunological fortress, with its ability to exclude unwanted intruders a boon when preventing infection but a burden when trying to deliver vital medicines. Researchers in China have now turned to an unusual source—pig semen—to develop eye drops that can deliver cancer drugs to the back of the eye.
Fierce Biotech
AstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars dataset
AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and efficacy profile have so far failed to separate it from traditional CAR-T therapies.
Fierce Biotech
After local tumor approval, Novocure touts positive data in metastatic pancreatic cancer
After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical data for its electric field-based treatment in metastatic cases of the aggressive disease.
Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its wholly owned subsidiary, Otsuka America, in a deal that could also deliver up to $525 million in milestone payments tied to assets in development.
FDA Grants Accelerated Approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for Recurrent Respiratory Papillomatosis
Opentrons Raises $40M in Series E to Expand Its Robotics, Software, Data Infrastructure
100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and Nomic
Postmarketing Requirements and Commitments: Searchable Database
FDA Rationale for Breakpoints Recognition Decision: Minocycline for Stenotrophomonas maltophilia
No Nonsense: David Liu Lauds Progress in Disease-Agnostic Gene Editing at ESGCT
-
Uncategorized7 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News7 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized6 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized5 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology7 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
-
BioPharma Dive – AI / Data7 months agoAstraZeneca lung drug gets ‘surprise’ win in COPD trials
Scan to Read